Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2

Patent metadata

Field	Value
Publication number	US-12247066-B2
Application number	US-201817272027-A
Country	US
Kind code	B2
Filing date	Aug 28, 2018
Priority date	Aug 28, 2018
Publication date	Mar 11, 2025
Grant date	Mar 11, 2025

Abstract

The present invention refers to a new monoclonal antibody or fragment thereof, called 14F5F6, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

First claim

The invention claimed is:

1. A monoclonal antibody or an antigen-binding fragment thereof that specifically recognizes herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2),
wherein said antibody or the antigen-binding fragment thereof has a variable region of a heavy chain in which CDR1, CDR2, and CDR3 have amino acid sequences defined in SEQ ID No:3, SEQ ID No:4, and SEQ ID No: 5, respectively, and at the same time has a variable region of a light chain in which CDR1, CDR2 and CDR3 have amino acid sequences defined in SEQ ID No:6, SEQ ID No:7 and SEQ ID No:8, respectively.

2. A monoclonal antibody or an antigen-binding fragment thereof that specifically recognizes herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), wherein said monoclonal antibody or the antigen-binding fragment thereof has a variable region of a heavy chain in which CDR1, CDR2 and CDR3 are encoded by sequences defined with SEQ ID No:11, SEQ ID No:12, and SEQ ID No:13, respectively, and has a variable region of a light chain in which CDR1, CDR2, and CDR3 are encoded by sequences defined with SEQ ID No:14, SEQ ID No:15, and SEQ ID No: 16, respectively.

3. The monoclonal antibody or the antigen-binding fragment thereof according to claim 1 , wherein the monoclonal antibody or the antigen-binding fragment thereof is specific to protein VP21 of a capsid of the HSV-1 and the HSV-2.

4. The monoclonal antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antibody is a humanized or a chimeric antibody.

5. A pharmaceutical composition for treatment and/or prophylaxis of infection caused by HSV-1 and/or HSV-2, comprising: the monoclonal antibody or the antigen-binding fragment thereof of claim 1 ; and a pharmaceutically acceptable carrier.

6. A method for detection of HSV-1 and/or HSV-2 in a sample, comprising:
contacting the sample with the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 ;
and detecting binding of the antibody or the fragment thereof to the HSV-1 and/or the HSV-2.

7. The method according to claim 6 wherein a technique used in the detecting the binding of the antibody or the fragment thereof to the HSV-1 and/or the HSV-2 is at least one technique selected from the group consisting of ELISA, immunofluorescence, immunohistochemistry, immunochromatography, flow cytometry, cell sorter, immunoprecipitation and Western blot.

8. A method for detection of HSV-1 and/or HSV-2 in a sample, comprising:
contacting the sample with the monoclonal antibody or the antigen-binding fragment according to claim 1 ; and
detecting binding of the antibody or the fragment thereof to the HSV-1 and/or the HSV-2,
wherein the antibody or the fragment thereof is conjugated with a marker that allows the detection.

9. The method according to claim 8 , wherein the marker is at least one material selected from the group consisting of fluorophores, biotin, radioisotopes, metals, and enzymes.

10. The method according to claim 8 , wherein the antibody or the fragment thereof is immobilized in a solid support.

11. The method according to claim 10 , wherein the solid support is at least one material selected from the group consisting of nitrocellulose, cellulose, polyethylene, and nylon.

12. The method according to claim 6 , wherein the sample is taken from part of a body of a subject or a material selected from the group consisting of a mouth, a skin, an eye, a mucosa swab, and brain-spinal fluid.

13. A method of treatment or prophylaxis of an infection by HSV-1 and/or HSV-2, comprising: administering the pharmaceutical composition of claim 5 to a subject in need thereof.

14. The method according to claim 13 , wherein the composition is administered intramuscularly.

Assignees

• Univ Pontificia Catolica Chile
• Fundacion Copec Univ Catolica

Inventors

• Kalergis Parra Alexis
• Bueno Ramírez Susan
• Gonzalez Muñoz Pablo

Classifications

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title

• G01N2333/035

  Herpes simplex virus I or II · CPC title

• G01N33/577

  involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)} · CPC title

• G01N33/56994

  Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title